The following suggested responses are provided to assist you in responding to questions about Guidelines/Clinical Document:
The American College of Cardiology (ACC or the College) has promulgated policies governing embargoes and the disclosure of scientific research results contained in late-breaking clinical trial presentations and abstracts. The premature unauthorized disclosure of embargoed results and/or data in any format constitutes a breach of the embargo policy. Authors, presenters, reviewers, committee members, members, company sponsors, and/or anyone (the “Parties” or “Party”) determined by the College to have violated the embargo policies shall be subject to ACC’s disciplinary procedures and sanctions related to embargo violations.
The Parties must comply with the ACC embargo policies, which state that scientific study results presented during the Annual Scientific Session or any other College sponsored scientific meeting must not be released publicly or privately prior to the start of the session in which the late breaking trial is presented at the Annual Scientific Session, other College sponsored scientific meeting or an ACC-sponsored press conference, whichever comes first. Some, though not all, LBCTs may be selected for an ACC press conference. LBCTs not selected for a press conference remain under embargo until the start of the session in which the late breaking trial is presented. Presentation of scientific research results at satellite meetings or press conferences in any format prior to the scheduled Annual Scientific Session or other College sponsored scientific meeting presentation is strictly forbidden. In the event that media representatives contact any Party any information must be given with the understanding that scientific research results are to remain under embargo until the time of presentation or ACC-sponsored press conference. Responsibility for information shared in this manner rests solely with the disclosing Party. Parties must seek prior ACC approval before publicly revealing any embargoed content related to public health concerns or required disclosures (e.g., SEC requirements). The ACC Presidential Team, CEO, press staff and meeting co-chairs will be available to work with the disclosing Party to develop an acceptable release of the required information.
These policies will be strictly enforced and violations will be enforced with disciplinary actions.
All abstracts submitted in connection with the Annual Scientific Session or other College sponsored scientific meeting are disclosed to members of the peer review selection committee, as well as to ACC employees and contractors as necessary. Abstracts accepted for presentation will be published in the Journal of the American College of Cardiology (JACC) in advance of the Annual Scientific Session or other College sponsored scientific meeting, and will be considered under embargo until released according to the JACC embargo schedule. Abstracts not accepted for presentation are not published and will not be disclosed outside of ACC and persons associated with the selection process (e.g., the peer review committee) and are not subject to the embargo policy. Although ACC and ACC employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material. Primary responsibility for compliance with any disclosure or nondisclosure requirements resides solely with the researchers and/or research sponsors.
If presented work is to be published in a peer-reviewed publication concurrent with the Annual Scientific Session or other College sponsored scientific meeting, it is the sole responsibility of the author or presenter to notify the ACC press office of the publication’s name and date of publication. This will allow ACC to work with the publication to coordinate embargo of the material.
Manuscripts are considered for review only under the conditions that they are not under consideration elsewhere and that the data presented have not appeared on the internet or have not been previously published (including symposia, proceedings, transactions, books, articles published by invitation and preliminary publications of any kind except abstracts not exceeding 400 words). On acceptance, written transfer of copyright to the American College of Cardiology Foundation, signed by all authors, will be required. Elsevier Inc. will maintain copyright records for the College.
Each author must have contributed significantly to the submitted work. If there are more than 4 authors, the contribution of each must be substantiated in the cover letter. If authorship is attributed to a group (either solely or in addition to 1 or more individual authors), all members of the group must meet the full criteria and requirements for authorship. To save space, if group members have been listed, the article should be referenced rather than reprinting the list. The Editors consider authorship to include all of the following:
- conception and design or analysis and interpretation of data, or both
- drafting of the manuscript or revising it critically for important intellectual content
- final approval of the manuscript submitted
Participation solely in the collection of data does not justify authorship but may be appropriately acknowledged in the Acknowledgment section. Manuscripts must be submitted with a cover letter stating that
- the paper is not under consideration elsewhere
- none of the paper's contents have been previously published
- all authors have read and approved the manuscript
- the full disclosure of any potential conflict of interest (see Conflict of Interest Policy)
Exceptions must be explained. The corresponding author should be specified in the cover letter. All editorial communications will be sent to this author.